Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mercedes Robledo

Showing results (181-190 of 215) with videos related to

Pageof 22
Sort By:
Nature Genetics|June 21, 2011
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytomaIñaki Comino-Méndez, Francisco J Gracia-Aznárez, Francesca Schiavi, et al.
Cancer Communications (London, England)|May 4, 2023
DLST mutations in pheochromocytoma and paraganglioma cause proteome hyposuccinylation and metabolic remodelingSara Mellid, Fernando García, Luis Javier Leandro-García, et al.
The Journal of Clinical Endocrinology and Metabolism|March 22, 2023
Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic ResponsesAlessa Fischer, Simon Kloos, Umberto Maccio, et al.
The Journal of Clinical Endocrinology and Metabolism|February 5, 2019
Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective StudySegolene Hescot, Maria Curras-Freixes, Timo Deutschbein, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 17, 2018
Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patientsBruna Calsina, Maria Currás-Freixes, Alexandre Buffet, et al.
The Journal of Clinical Endocrinology and Metabolism|August 14, 2020
CD133 Expression in Medullary Thyroid Cancer Cells Identifies Patients with Poor PrognosisAlfonso Cordero-Barreal, Eduardo Caleiras, Evangelina López de Maturana, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|May 29, 2025
Expression of Homo Sapiens (Hsa)-miR-139-5p as a Clinically Feasible Prognostic Marker for Differentiated Thyroid CancerNatalia Martínez-Puente, Ignacio Ruz-Caracuel, Luis J Leandro-García, et al.
Plos Genetics|September 5, 2009
The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factorsIñigo Landa, Sergio Ruiz-Llorente, Cristina Montero-Conde, et al.
Clinical and Translational Medicine|August 18, 2022
Comprehensive molecular analysis of immortalization hallmarks in thyroid cancer reveals new prognostic markersCristina Montero-Conde, Luis Javier Leandro-García, Ángel M Martínez-Montes, et al.
The Lancet. Oncology|January 15, 2010
SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytomaJean-Pierre Bayley, Henricus P M Kunst, Alberto Cascon, et al.
Pageof 22

Showing results (181-190 of 215) with videos related to

Sort By:
Pageof 22
Nature Genetics|June 21, 2011
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytomaIñaki Comino-Méndez, Francisco J Gracia-Aznárez, Francesca Schiavi, et al.
Cancer Communications (London, England)|May 4, 2023
DLST mutations in pheochromocytoma and paraganglioma cause proteome hyposuccinylation and metabolic remodelingSara Mellid, Fernando García, Luis Javier Leandro-García, et al.
The Journal of Clinical Endocrinology and Metabolism|March 22, 2023
Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic ResponsesAlessa Fischer, Simon Kloos, Umberto Maccio, et al.
The Journal of Clinical Endocrinology and Metabolism|February 5, 2019
Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective StudySegolene Hescot, Maria Curras-Freixes, Timo Deutschbein, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 17, 2018
Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patientsBruna Calsina, Maria Currás-Freixes, Alexandre Buffet, et al.
The Journal of Clinical Endocrinology and Metabolism|August 14, 2020
CD133 Expression in Medullary Thyroid Cancer Cells Identifies Patients with Poor PrognosisAlfonso Cordero-Barreal, Eduardo Caleiras, Evangelina López de Maturana, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|May 29, 2025
Expression of Homo Sapiens (Hsa)-miR-139-5p as a Clinically Feasible Prognostic Marker for Differentiated Thyroid CancerNatalia Martínez-Puente, Ignacio Ruz-Caracuel, Luis J Leandro-García, et al.
Plos Genetics|September 5, 2009
The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factorsIñigo Landa, Sergio Ruiz-Llorente, Cristina Montero-Conde, et al.
Clinical and Translational Medicine|August 18, 2022
Comprehensive molecular analysis of immortalization hallmarks in thyroid cancer reveals new prognostic markersCristina Montero-Conde, Luis Javier Leandro-García, Ángel M Martínez-Montes, et al.
The Lancet. Oncology|January 15, 2010
SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytomaJean-Pierre Bayley, Henricus P M Kunst, Alberto Cascon, et al.
Pageof 22